HC Wainwright Forecasts Strong Price Appreciation for NovoCure (NASDAQ:NVCR) Stock

NovoCure (NASDAQ:NVCR) had its price objective boosted by analysts at HC Wainwright from $47.00 to $49.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s price target points to a potential upside of 258.45% from the stock’s current price.

Several other analysts also recently issued reports on the stock. Evercore set a $20.00 price target on shares of NovoCure in a research report on Monday, January 5th. Wedbush reiterated a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $26.93.

NovoCure Stock Performance

Shares of NVCR opened at $13.67 on Thursday. NovoCure has a one year low of $9.82 and a one year high of $21.55. The company has a market cap of $1.53 billion, a PE ratio of -11.20 and a beta of 0.73. The stock has a 50-day moving average of $12.73 and a 200-day moving average of $12.65. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The business had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative return on equity of 38.82% and a negative net margin of 20.79%.The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.61) earnings per share. On average, equities research analysts predict that NovoCure will post -1.3 EPS for the current fiscal year.

Institutional Trading of NovoCure

Institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of NovoCure by 56.7% in the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock valued at $512,000 after purchasing an additional 10,394 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock worth $1,336,000 after purchasing an additional 2,502 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in NovoCure by 5.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock valued at $17,707,000 after buying an additional 52,180 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of NovoCure during the 1st quarter worth approximately $87,000. Finally, Simon Quick Advisors LLC boosted its stake in shares of NovoCure by 53.2% in the 2nd quarter. Simon Quick Advisors LLC now owns 21,927 shares of the medical equipment provider’s stock worth $390,000 after buying an additional 7,618 shares during the last quarter. Institutional investors own 84.61% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.